Following training in haematology/oncology and stem cell transplantation at Imperial College London, Professor Tariq I Mughal has held haematology/oncology leadership roles in cancer centres of excellence in London, Manchester and Denver. From an early stage in his career, he has been interested in precision haematologic cancer medicine and breast cancer. He now practices in Boston and London, and is a member of many learned societies. He is a professor of medicine and founder of Alpine Oncology Foundation dedicated to improve haematologic cancer care in economically challenged countries. He has published over 130 peer-reviewed scientific publications, 30 book chapters and authored/edited 13 books on cancers.Following training inhematology/oncology in Padova, Professor Tiziano Barbui was appointed initially as a Professor, and later as the head of the department of Haematology at the (then) Ospedale Riuniti, and now Papa Giovanni XXIII, in Bergamo (Italy). He is a past-President of the Italian Society of Haematology, and chair of the Lupus Anticoagulant Subcommittee of the International Society of Thrombosis and Haemostasis. He currently leads the Italian GIMEMA group and is the co-chair of the European-Leukemia-Net working group on Myeloproliferative Disorders. He has published over 450 peer-reviewed scientific publications and authored/edited several books and chapters.

This practical guide, written by experts in the field, is essential reading for oncologists, haematologists, and other health care professionals interested in the field of MPNs.

• 1: Tariq I. Mughal and Tiziano Barbui: History of the myeloproliferative neoplasms 2: Srinivas K. Tantravahi, Jamshid S. Khorashad, and Michael W.Deininger: Genomic landscape of myeloproliferative neo-plasms 3: Angela G. Fleischman and Richard A. Van Etten: Pathogenesis of myeloproliferative neoplasms 4: Hans Michael Kvasnicka and Jüergen Thiele: Haematopathology of myeloproliferative neoplasms 5: Michele Baccarani, Fausto Castagnetti, Gabriele Gugliotta, Francesca Palandri, Simona Soverini, and Gianantonio Rosti: Prognostic factors of chronic myeloid leukaemia 6: Paola Guglielmelli and Alessandro M. Vannucchi: Molecular risk stratification of Myeloproliferative Neoplasms 7: Tariq I. Mughal: Chronic myeloid leukaemia 8: Tiziano Barbui and Guido Finazzi: Polycythaemia vera 9: Claire Harrison, Yan Beauverd, and Donal McLorran: Myelofibrosis 10: Carlos Besses, Beatriz Bellosillo, and Alberto Alvarez-Larrán: Essential thrombocythemia 11: Jason Gotlib: Systemic mastocytosis 12: Eric Padron, David Sallman, Tariq I. Mughal, and Alan F. List: Myelodysplastic syndromes/myeloproliferative neoplasms 13: Andreas Reiter and Nicholas C. P. Cross: Eosinophilia-associated myeloproliferative neoplasms 14: Omar Abdelwahab, Raajit Rampal, Catriona Jamieson, and Tariq I. Mughal: Transformation of myeloproliferative neoplasms to acute leukaemia 15: Daniel Egan and Jerald P. Radich: Monitoring efforts in myeloproliferative neoplasms 16: Alessandro Rambaldi and Nicholas Kröger: Stem cell transplantation for BCR-ABL1-postive and negative myeloproliferative neoplasms 17: Holly L. Geyer, Deepti Radia, Nicholas Sarlis, and Ruben A. Mesa: Assessment of disease burden in patients with myeloproliferative neoplasms 18: Giovanni Barosi and Gianni Tognoni: Clinical trials in bcr-abl1-negative myeloproliferative neo-plasms